>
Research and development $12,299 8,712 $33,381 28,362
General and administrative $1,851 1,632 $6,054 5,733
Total operating expenses 14,150 10,344 39,435 34,095
Loss from operations (12,203) (8,175) (22,364) (26,299)
Other income, net 1,070 635 3,187 1,389
Net loss $(11,133) $(7,540) $(19,177) $(24,910)
Basic and diluted net loss per
common share $(0.26) $(0.22) $(0.46) $(0.76)
Shares used in computing basic and
diluted net loss per common share 42,528 34,573 41,384 32,778
Condensed Balance Sheets
(in thousands)
September 30, December 31,
2007 2006
(unaudited)
Cash, cash equivalents, restricted
cash $81,650 $64,087
and marketable securities
Total assets $89,095 $71,187
Deferred revenue $7,497 $19,591
Total liabilities $20,718 $29,433
Total liabilities and stockholders'
equity $89,095 $71,187
Shares issued and outstanding 42,584 35,390
'/>"/>SOURCE Kosan Biosciences Incorporated Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related biology technology :1.
Kosan Biosciences to Present at the Bear Stearns 20th Annual Healthcare Conference2.
Kosan Biosciences to Present at the 2007 UBS Global Life Sciences Conference3.
Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum4.
Kosan Biosciences to Host Research & Development Day on October 31, 20075.
Kosan to Reacquire Epothilone Program From Roche6.
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients7.
YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 268.
Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering9.
BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.10.
Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets11.
China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results